NICE TA665 - Upadacitinib for treating severe rheumatoid arthritis
MHRA Drug Safety Update, 26 April 2023
1.1 Upadacitinib, with methotrexate, is recommended as an option for treating active rheumatoid arthritis in adults whose disease has responded inadequately to intensive therapy with a combination of conventional disease-modifying antirheumatic drugs (DMARDs), only if:
• disease is severe (a disease activity score [DAS28] of more than 5.1) and
• the company provides upadacitinib according to the commercial arrangement.